PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30771350-5	2019	These effects were alleviated by C3a receptor antagonist SB290157 and were further validated by C3a receptor siRNA in OA-treated SH-SY5Y cells.	SB 290157	57-65	complement C3	Homo sapiens	33-36	
16154494-0	2005	The C3a receptor antagonist SB 290157 has agonist activity.	SB 290157	28-37	complement C3	Homo sapiens	4-7	
33746964-8	2021	In isolated mitochondria from H2O2-treated cells C3a increased mitochondrial Ca2+ uptake, that could be inhibited by C3aR antagonism (SB290157), mitochondrial Ca2+ uniporter blocker (Ru360), and Galphai-protein inhibition (pertussis toxin, PTX); and inhibited mitochondrial repiration in an SB290157- and PTX-dependent manner.	SB 290157	134-142	complement C3	Homo sapiens	49-52	
33746964-8	2021	In isolated mitochondria from H2O2-treated cells C3a increased mitochondrial Ca2+ uptake, that could be inhibited by C3aR antagonism (SB290157), mitochondrial Ca2+ uniporter blocker (Ru360), and Galphai-protein inhibition (pertussis toxin, PTX); and inhibited mitochondrial repiration in an SB290157- and PTX-dependent manner.	SB 290157	291-299	complement C3	Homo sapiens	49-52	
24470120-7	2014	C3 gene expression in bone was increased in the high bone turnover states of ovariectomy (OVX) or a receptor activator of NF-kappaB ligand (RANKL) injection, and blocking the action of C3a with the daily administration of SB290157 resulted in the attenuation of bone formation elevated by OVX and the exacerbation of bone loss.	SB 290157	222-230	complement C3	Homo sapiens	0-2	
24470120-7	2014	C3 gene expression in bone was increased in the high bone turnover states of ovariectomy (OVX) or a receptor activator of NF-kappaB ligand (RANKL) injection, and blocking the action of C3a with the daily administration of SB290157 resulted in the attenuation of bone formation elevated by OVX and the exacerbation of bone loss.	SB 290157	222-230	complement C3	Homo sapiens	185-188